solv
-5%
est. 2Y upside i
Rank
#2407
Sector
HealthTech
Est. Liquidity
~4Y
Data Quality
Data: LowSolv offers a high-risk equity package given a $1B stale valuation and intense competition from Epic, Teladoc, and big tech.
Last updated: July 21, 2026
AI-first platform drives rapid adoption and IPO hype, expanding multiple to 30x on $90M revenue, yielding 150% net upside after 20% dilution.
Multiple converges toward public comp range of 4-7x, but at 12x still above comps; modest revenue growth leads to ~8% gross upside, net -12% after dilution.
Intense competition from incumbents and slowing growth compress multiple to 5x; revenue falls short; net downside of -75% after dilution.
Preference Stack Risk
moderateFunding Intensity
10%Total preferred stock of $95.1M represents 9.5% of current valuation, moderate preference overhang.
Dilution Risk
highWith $95M total funding and no recent round, likely to raise more capital, diluting common by ~20%.
Secondary Liquidity
noneNo active secondary market; liquidity tied to IPO or acquisition.
Questions to Ask at the Interview
Strategic questions based on solv's data — designed to show you've done your homework.
- 1
“How does Solv plan to differentiate from Epic and Teladoc in the AI-driven healthcare space?”
- 2
“What are the unit economics for the marketplace versus SaaS subscriptions, and how do they scale?”
- 3
“What is the expected timeline to liquidity, and does the company consider secondary sales for employees?”
Community
Valuation Sentiment
Our model estimates -5% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.